U.S. Communications Stock News

In February 2026, Kimco Realty reported fourth-quarter and full-year 2025 results showing higher annual revenue and net income, completed a US$195.58 million buyback program repurchasing 11,200,000 shares, issued 2026 net income guidance of US$0.80–US$0.84 per share, and declared higher common and ongoing preferred dividends payable in March and April 2026. An interesting aspect is how the combination of rising full-year earnings, a 4.0% common dividend increase, and completion of a...

Recent coverage highlighted a past market rotation that boosted interest in high-yield dividend REITs, with Omega Healthcare Investors drawing attention for its income profile and cash flow resilience compared with growth-focused technology names. The spotlight on Omega’s above-benchmark yield, strong institutional ownership, and healthcare-focused real estate portfolio underlines its role as an income-oriented option for investors seeking stability during periods of market volatility. We’ll...

In recent days, UP Fintech Holding Ltd saw a surge in bullish options activity, with call option volumes tripling and implied volatility rising ahead of its now-released earnings report. This unusual options positioning highlights how derivatives traders are tactically using leverage to express expectations about UP Fintech’s near‑term fundamentals and potential earnings surprises. We’ll now examine how this spike in bullish options activity ahead of earnings could influence UP Fintech’s...

If you are wondering whether EVERTEC's current share price still reflects its true potential, or if the market has marked it down too far, this article is for you. With EVERTEC's share price at US$25.78 and share price returns of a 2.2% decline over 7 days, 13.5% decline over 30 days, 10.1% decline year to date, 21.4% decline over 1 year, 29.3% decline over 3 years and 28.1% decline over 5 years, many investors are asking what the stock is really worth now. Recent coverage has focused on...

Resideo Technologies (REZI) is drawing attention after recent trading left the shares at a last close of US$34.60, with a mixed return profile over the past year and over multi-year periods. See our latest analysis for Resideo Technologies. Recent trading has been choppy, with a 1-day share price return of 5.77% and a 7-day share price return of 3.43% pulling back some of the gains from a 90-day share price return of 8.77%. At the same time, the 1-year total shareholder return of 77.44% and...

What recent returns say about QMMM Holdings (QMMM) QMMM Holdings (QMMM) has attracted attention after a 19.4% one day move, a return of 19.4% over the past 3 months, and a year to date gain of 87.44%. See our latest analysis for QMMM Holdings. That surge in the 1 day share price return and the latest share price of $119.4 comes on top of a 90 day share price return of 19.4% and a very large year to date share price gain. The 1 year total shareholder return is also very large, suggesting...

Edwards Lifesciences, ticker NYSE:EW, plans to launch new left atrial appendage closure products in 2026. The products will build on the company’s existing surgical franchise to enter a growing treatment segment for atrial fibrillation patients. The move broadens Edwards Lifesciences’ portfolio beyond its core offerings in structural heart therapies. Edwards Lifesciences, trading at $82.44, is preparing to extend its reach with new left atrial appendage closure devices that sit alongside...

If you are wondering whether Helmerich & Payne at around US$35.13 is offering good value today, you are not alone. This article will walk through what the current market price might be implying. The stock has seen returns of 5.8% over the past week, 8.8% over the last 30 days, 17.3% year to date and 32.8% over the past year, while the 3 year return is a 4.0% decline and the 5 year return is 43.5%. Recent price moves sit against a backdrop of ongoing interest in energy and drilling companies,...

Why Gossamer Bio’s PROSERA readout matters now Gossamer Bio (GOSS) has drawn fresh attention after releasing topline Phase 3 PROSERA data for seralutinib in pulmonary arterial hypertension and scheduling a special call to review the results and potential next steps with regulators. See our latest analysis for Gossamer Bio. The unveiling of the PROSERA Phase 3 topline data and the planned FDA discussions come after a sharp reset in sentiment, with a 30 day share price return of 84.32% decline...

RenaissanceRe Holdings’ board previously approved a quarterly dividend increase to US$0.41 per share from US$0.40, payable on March 31, 2026 to shareholders of record on March 13, 2026, and reported completing share repurchases totaling 3,065,414 shares across two programs for a combined US$780.48 million. The company’s three-decade pattern of annual dividend increases, paired with recently completed buybacks that retired nearly one-twentieth of its share base, highlights a sustained...

Krystal Biotech received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for KB707 in advanced non small cell lung cancer. The company reported progress across its gene therapy pipeline, including pivotal ophthalmology trials with data expected next year. These updates extend Krystal Biotech’s focus beyond rare skin diseases into larger indications such as lung cancer. For investors following Krystal Biotech, ticker NasdaqGS:KRYS, the RMAT news comes with the shares at $274.59...

Graco (NYSE:GGG) board member Brett C. Carter has resigned from the board. Carter cited personal and professional commitments for his departure, with no disagreements related to Graco reported. His resignation affects board roles tied to key areas such as audit and compensation oversight. Graco, known for its equipment for fluid handling across industrial and commercial applications, operates in a part of the market that can be influenced by broader trends in manufacturing, construction,...

If you are wondering whether Voyager Technologies is attractively priced or just a value trap, this article walks through what the numbers are actually saying about the stock. The share price recently closed at US$26.82, with a 3% return over the past week, a 27.7% decline over the last 30 days, and a 3.5% decline year to date, which may signal shifting views on its potential and risk. Recent news coverage around Voyager Technologies has focused on its position in the capital goods space and...

If you are wondering whether Acadia Healthcare Company is attractively priced or still a value trap after a tough run, this breakdown is designed to give you a clear view of where the stock stands today. The shares last closed at US$17.38, with returns of 3.6% over 7 days, 14.1% over 30 days, 21.6% year to date, but a 57.3% decline over 1 year and a 78.4% decline over 3 years. This raises questions about how the current price lines up with underlying value. Recent news coverage has largely...

Recent share performance and business context Copart (CPRT) shares have pulled back recently, with a 1 day return of around a 3% decline, and weaker performance over the past week, month, and past 3 months drawing fresh attention from investors. The company runs online auctions and vehicle remarketing services across multiple countries, processing and selling vehicles over the internet for dismantlers, rebuilders, dealers, exporters, and the public. See our latest analysis for Copart. At a...

Credo Technology Group Holding’s PCIe 6.0-capable Toucan retimer has achieved PCI-SIG compliance, confirming it meets industry standards for the latest PCIe 6.0 technology. The company also introduced new connectivity products, including the Blue Heron 224G AI scale-up retimer and additional PCIe 6.0-capable devices aimed at AI and data center workloads. These launches focus on higher bandwidth and reliability for customers building AI clusters and advanced data center infrastructure. Credo...

If you are wondering whether Centuri Holdings' share price still reflects good value, or if the recent excitement has already been priced in, this article will walk you through what the numbers indicate about the stock. The shares last closed at US$31.24, with returns of 0.7% over 7 days, 10.0% over 30 days, 21.0% year to date and 72.1% over the past year. This has naturally raised questions about how the current price compares with underlying value. Recent news flow around Centuri Holdings...

Regions Financial (RF) has drawn fresh attention after major firms including J.P. Morgan and UBS raised their views on the stock, even as recent quarterly results fell short of some market estimates. See our latest analysis for Regions Financial. At a share price of US$28.71, Regions Financial has recently seen a 12.94% 90 day share price return and a 27.80% 1 year total shareholder return, suggesting near term momentum alongside stronger multi year gains as investors reassess earnings...

Genuine Parts plans to separate into two independent, tax free companies by Q1 2027. The split will create a dedicated Global Automotive business and a separate Global Industrial business. The company expects the separation to sharpen business focus and reshape its long term direction. For NYSE:GPC shareholders, this planned breakup comes after a challenging stretch for the stock. Shares are at $116.16, with a 21.1% decline over the past week and a 15.6% decline over the past month. Over 3...

If you are wondering whether Collegium Pharmaceutical at around US$44.85 is good value or looking fully priced, the key is understanding how its current share price stacks up against a few different valuation checks. The stock has had a mixed run recently, with a 2.1% decline over the last 7 days and a 1.4% decline over the last 30 days, even though the 1 year return sits at 53.6% and the 3 year return at 67.4%. Recent attention on Collegium has focused on its position within the US...

In the past few days, law firm Kirby McInerney LLP announced it is investigating Alvotech and certain executives for potential federal securities law violations after the FDA issued a complete response letter citing a failed facility inspection for its AVT05 biologics license application. This combination of regulatory setback and investor scrutiny raises fresh questions about Alvotech’s quality controls, regulatory risk management, and disclosure practices around its biosimilar...

MFA Financial (MFA) is on investor watch after posting annual revenue of US$325.4 million and net income of US$135.7 million, with recent returns mixed over the day, week, month and past 3 months. See our latest analysis for MFA Financial. At a share price of US$9.90, MFA Financial has seen short term share price softness alongside a positive 3 month share price return and a stronger 1 year total shareholder return of 11.27%. This suggests that recent price swings are occurring within a more...

Spectrum Brands Holdings (SPB) has drawn fresh attention after recent trading left the stock with a one-month return of 22% and a gain of 34.1% over the past three months, sharpening interest in its consumer brands portfolio. See our latest analysis for Spectrum Brands Holdings. That recent run sits on top of a 31.43% year to date share price return as the stock trades at US$78.91. The 1 year total shareholder return of 3.46% and 3 year total shareholder return of 33.70% suggest momentum has...

Advanced Energy Industries (NasdaqGS:AEIS) is actively pursuing acquisitions to expand its presence, with recent deals focused on industrial and medical technology. Management has highlighted a busy acquisition pipeline and points to recent integration of new technology as evidence that its inorganic growth push is gaining traction. The company is signaling that further deals in industrial and medical markets are a priority, with the goal of reshaping its portfolio around higher value...